Veracyte is a leading molecular diagnostics company based in South San Francisco, CA, specializing in providing exceptional cancer care through advanced diagnostic tests. Their portfolio includes genomic sequencing classifiers for thyroid, prostate, breast, and bladder cancers, as well as an envisia genomic classifier for interstitial lung disease. Veracyte's tests empower clinicians with high-value insights, enabling more informed and confident decision-making in cancer diagnosis and treatment.
With a proven framework and rigorous approach to diagnostics, Veracyte collaborates closely with clinicians and scientists to identify unmet needs and develop innovative solutions. Their tests have benefited over 400,000 patients worldwide, addressing the needs of the approximately 7 million people diagnosed with cancers that their tests target each year. By making leading diagnostics accessible globally, Veracyte aims to elevate the standard of care and transform cancer treatment for patients around the world.
Generated from the website